Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
阅读说明：本技术 取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其作为磷酸二酯酶抑制剂的用途 (Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors ) 是由 M·安德鲁斯 D·R·格雷夫 B·诺雷马克 于 2018-12-14 设计创作，主要内容包括：本发明涉及具有磷酸二酯酶抑制活性的新型取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其在治疗中的用途、包含所述化合物的药物组合物以及用化合物(I)治疗疾病的方法。<Image he="426" wi="700" file="DDA0002630966310000011.GIF" imgContent="drawing" imgFormat="GIF" orientation="portrait" inline="no"></Image>(The present invention relates to novel substituted azetidine dihydrothienopyridines having phosphodiesterase inhibitory activity and their use in therapy, pharmaceutical compositions comprising said compounds and methods of treating diseases with compound (I).)
1. A compound of the general formula (I)
Wherein
R1Selected from phenyl, 6-membered heteroaryl, phenoxy and 6-membered heteroaryloxy; all of these groups are optionally substituted with one or more groups independently selected from R3Substituted with the substituent(s);
R2is selected from (C)3-C7) Cycloalkyl, bridge (C)3-C7) Cycloalkyl and (4-7 membered) heterocycloalkyl; all of these groups are optionally substituted with one or more groups independently selected from R4Substituted with the substituent(s);
R3selected from halogen, -CN, (C)1-C4) Alkyl, halo (C)1-C4) Alkyl, hydroxy (C)1-C4) Alkyl and (C)3-C6) A cycloalkyl group;
R4selected from fluorine, -CN, -OH, (C)1-C4) Alkyl, haloGeneration (C)1-C4) Alkyl, hydroxy (C)1-C4) Alkyl, -ORx、-S(O)2Rx、-S(O)2NRaRb、-C(O)Rx、-C(O)(ORx) and-C (O) NRaRb；
RxIs selected from (C)1-C4) Alkyl and (C)3-C6) A cycloalkyl group; and is
RaAnd RbIndependently selected from hydrogen, (C)1-C4) Alkyl and (C)3-C6) A cycloalkyl group; and is
S represents a chiral sulphur atom having (R) stereochemistry; or
Pharmaceutically acceptable salts, enantiomers, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates, and solvates thereof.
2. A compound according to claim 1, wherein R1Is optionally substituted by one R3Substituted phenyl or phenoxy.
3. A compound according to claim 1 or 2, wherein R3Is fluorine.
4. The compound of any one of claims 1-3, wherein R2Is piperidinyl, pyrrolidinyl or tetrahydropyranyl, all of which are optionally substituted with one or more groups independently selected from R4Is substituted with the substituent(s).
5. A compound according to claim 4, wherein R2Is tetrahydropyranyl.
6. A compound according to any one of the preceding claims, selected from:
(1R) -5- (3- (4-fluorophenyl) azetidin-1-yl) -7- ((tetrahydro-2H-pyran-4-yl) amino) -2, 3-dihydrothieno [3,2-b ] pyridine 1-oxide;
(3R) -3- [ [ (1R) -5- [3- (4-fluorophenyl) azetidin-1-yl ] -1-oxo-2, 3-dihydrothieno [3,2-b ] pyridin-7-yl ] amino ] piperidine-1-carboxylic acid methyl ester;
(3R) -3- [ [ (1R) -5- (3- (4-phenylazetidin-1-yl) -1-oxo-2, 3-dihydrothieno [3,2-b ] pyridin-7-yl ] amino ] piperidine-1-carboxylic acid methyl ester;
(1R) -5- (3- (4-fluorophenoxy) azetidin-1-yl) -7- ((tetrahydro-2H-pyran-4-yl) amino) -2, 3-dihydrothieno [3,2-b ] pyridine-1-oxide;
(3S) -3- [ [ (1R) -5- [3- (4-fluorophenoxy) azetidin-1-yl ] -1-oxo-2, 3-dihydrothieno [3,2-b ] pyridin-7-yl ] amino ] pyrrolidine-1-carboxylic acid methyl ester;
1- [ (3S) -3- [ [ (1R) -5- [3- (4-fluorophenoxy) azetidin-1-yl ] -1-oxo-2, 3-dihydrothieno [3,2-b ] pyridin-7-yl ] amino ] pyrrolidin-1-yl ] ketene;
(1R) -5- (3-phenylazetidin-1-yl) -7- ((tetrahydro-2H-pyran-4-yl) amino) -2, 3-dihydrothieno [3,2-b ] pyridine-1-oxide;
or pharmaceutically acceptable salts, enantiomers, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates, and solvates thereof.
7. A pharmaceutical composition comprising a compound according to any one of claims 1-6 and a pharmaceutically acceptable vehicle or excipient or a pharmaceutically acceptable carrier.
8. Use of a compound according to any one of claims 1 to 6 for the preparation of a pharmaceutical composition.
9. Use of a compound according to claim 8 for the preparation of a pharmaceutical composition for the treatment or amelioration of a disease, disorder or condition that is responsive to PDE4 inhibitory activity.
10. The use according to claim 9, wherein the disease, disorder or condition is proliferative and inflammatory skin diseases, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, including irritant and allergic contact dermatitis, hand dermatitis, psoriasis vulgaris, reverse psoriasis, psoriatic arthritis, spondyloarthritis, epidermal inflammation, alopecia areata, rosacea, skin atrophy, steroid induced skin atrophy, skin photoaging, SAPHO syndrome (synovitis, acne, impetigo, hypertrophic bone and osteitis), acne vulgaris, hidradenitis suppurativa, urticaria, pruritus and eczema.
11. A compound according to any one of claims 1 to 6 for use as a medicament.
12. A compound according to claim 11 for use in the treatment or amelioration of a disease, disorder or condition that is responsive to PDE4 inhibitory activity.
13. A compound according to claim 12 for use in the treatment or amelioration of a skin disease, disorder or condition.
14. A compound according to claim 13 for use in the treatment of proliferative and inflammatory skin diseases, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis including irritant and allergic contact dermatitis, hand dermatitis, psoriasis vulgaris, reverse psoriasis, psoriatic arthritis, spondyloarthritis, epidermal inflammation, alopecia areata, rosacea, skin atrophy, steroid induced skin atrophy, skin photoaging, SAPHO syndrome (synovitis, acne, impetigo, pachulosis and osteitis), acne vulgaris, hidradenitis suppurativa, urticaria, pruritus and eczema.
15. A method of treatment or alleviation of a disease or a disorder or a condition which is responsive to PDE4 inhibitory activity, which method comprises the step of administering to a living animal body a therapeutically effective amount of a compound according to any one of claims 1-6.
16. A method of treating or ameliorating a skin disease, disorder or condition, the method comprising administering to a person suffering from at least one of said diseases an effective amount of one or more compounds according to any one of claims 1-6, optionally together with a pharmaceutically acceptable carrier or one or more excipients, optionally in combination with other therapeutically active compounds.
17. The method according to claim 17, wherein the skin disease, disorder or condition is selected from the group consisting of proliferative and inflammatory skin diseases, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, including irritant and allergic contact dermatitis, hand dermatitis, psoriasis vulgaris, reverse psoriasis, psoriatic arthritis, spondyloarthritis, epidermal inflammation, alopecia areata, rosacea, skin atrophy, steroid induced skin atrophy, skin photoaging, SAPHO syndrome (synovitis, acne, impetigo, hypertrophic bone and osteitis), acne vulgaris, hidradenitis suppurativa, urticaria, pruritus and eczema.
Technical Field
The present invention relates to novel substituted azetidine dihydrothienopyridines having phosphodiesterase inhibitory activity and their use in therapy, pharmaceutical compositions comprising the compounds and methods of treating diseases with the compounds.
Background
Phosphodiesterases are enzymes that catalyze the hydrolysis of cyclic AMP and/or cyclic GMP in cells to 5-AMP and 5-GMP, respectively, and thus are important for the cellular regulation of cAMP or cGMP levels. Of the 11 phosphodiesterases currently identified, Phosphodiesterase (PDE)4, PDE7 and PDE8 are cAMP selective. PDE4 is the most important regulator of cAMP expressed in immune and inflammatory cells such as neutrophils, macrophages and T-lymphocytes. Since cAMP is a key second messenger in the modulation of inflammatory responses, PDE4 has been found to modulate the inflammatory response of inflammatory cells by modulating pro-inflammatory cytokines such as TNF α, IL-2, IFN- γ, GM-CSF, and LTB 4. Therefore, inhibition of PDE4 is an attractive target for the treatment of inflammatory diseases such as asthma, Chronic Obstructive Pulmonary Disease (COPD), rheumatoid arthritis, atopic dermatitis, psoriasis, inflammatory bowel disease such as Crohn's disease, etc. (M.D. Houslay et al, Drug Discovery Today 10(22),2005, 1503) 1519). Since Atopic Dermatitis (AD) patients have elevated PDE activity, inhibition of PDE4 appears to be a viable treatment for AD as well (Journal of Investigative Dermatology (1986),87(3), 372-6).
The PDE4 gene family consists of at least 4 genes A, B, C and D, which have a high degree of homology (v. boswellsmith and D. spinoa, curr. opinion investig. drugs 6(11),2006, 1136-. These four PDE4 subtypes are differentially expressed in different tissues and cell types. Thus, PDE4B is expressed predominantly in monocytes and neutrophils but not in cortical and epithelial cells, whereas PDE4D is expressed in lung, cortex, cerebellum and T cells (c.kroegel and m.foerster, exp. opinion investig. drugs 16(1),2007, page 109-.
A number of PDE4 inhibitors have been investigated for their therapeutic effect on inflammatory diseases, mainly asthma and COPD.
WO 2006/111549, US 20070259846, WO 2009/050236, WO 2009/050242 and WO 2009/053268 (all of Boehringer ingelhan International) each disclose piperazine substituted dihydrothieno-pyrimidines for the treatment of respiratory or inflammatory diseases. These compounds are said to inhibit the PDE4 enzyme.
WO 2007/118793, WO 2009/050248 and WO 2013/026797 (all of the british invagren international corporation) each disclose piperidine substituted dihydrothieno-pyrimidines for the treatment of respiratory or inflammatory diseases. These compounds are said to inhibit the PDE4 enzyme.
WO 2014/066659(Tetra Discovery Partners) discloses bicyclic heteroaryl compounds which are said to be PDE4 inhibitors.
There is a continuing need to develop new PDE4 inhibitors that have a more favorable therapeutic window, i.e., have fewer side effects, while retaining their therapeutic efficacy.
Summary of The Invention
It is an object of the present invention to provide novel azetidine dihydrothienopyridines. In one aspect, the invention relates to PDE4 inhibitors that are useful as therapeutic agents for diseases mediated by PDE4, including skin diseases or conditions, inflammatory allergic diseases, autoimmune diseases; acute or chronic skin wound diseases, etc.
The compounds of the invention may have good oral bioavailability, solubility, absorption and metabolic stability. They may also have good safety profiles, making them more resistant than other PDE4 inhibitors.
The compounds of the invention may have low clearance in human liver microsomes, thus making them suitable for oral use.
The compounds of the invention may have an improved window of nausea and vomiting side effects relative to other PDE4 inhibitors, allowing them to be administered with a higher fold-over-PDE 4 potency for greater therapeutic effect.
In one aspect, the invention provides compounds of formula (I)
Wherein
R1Selected from phenyl, 6-membered heteroaryl, phenoxy and 6-membered heteroaryloxy; all of these groups are optionally substituted with one or more groups independently selected from R3Substituted with the substituent(s);
R2is selected from (C)3-C7) Cycloalkyl, bridge (C)3-C7) Cycloalkyl and (4-7 membered) heterocycloalkyl; all of these groups are optionally substituted with one or more groups independently selected from R4Substituted with the substituent(s);
R3selected from halogen, -CN, (C)1-C4) Alkyl, halo (C)1-C4) Alkyl, hydroxy (C)1-C4) Alkyl and (C)3-C6) A cycloalkyl group;
R4selected from fluorine, -CN, -OH, (C)1-C4) Alkyl, halo (C)1-C4) Alkyl, hydroxy (C)1-C4) Alkyl, -ORx、-S(O)2Rx、-S(O)2NRaRb、-C(O)Rx、-C(O)(ORx) and-C (O) NRaRb；
RxIs selected from (C)1-C4) Alkyl and (C)3-C6) A cycloalkyl group;
Raand RbIndependently selected from hydrogen, (C)1-C4) Alkyl and (C)3-C6) A cycloalkyl group; and is
S represents a chiral sulphur atom having (R) stereochemistry; and
pharmaceutically acceptable salts, enantiomers, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates, and solvates thereof.
In another aspect, the invention provides a pharmaceutical composition comprising a compound of the invention as defined above, together with a pharmaceutically acceptable vehicle or excipient or pharmaceutically acceptable carrier, and optionally one or more other therapeutically active compounds.
In another aspect, the invention provides the use of a compound of the invention in the manufacture of a pharmaceutical composition for the prevention, treatment, prevention or amelioration of a disease, disorder or condition that is responsive to PDE4 inhibitory activity.
In another aspect, the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition which is responsive to PDE4 inhibitory activity, which method comprises the step of administering to a living animal body a therapeutically effective amount of a compound of the invention.
Other objects of the present invention will be apparent to those skilled in the art from the following detailed description and examples.
Detailed Description
Definition of
The following terms used throughout the specification and appended claims have the indicated meanings:
the term "alkyl" is intended to mean a group obtained by removing one hydrogen atom from a branched or straight-chain hydrocarbon. The alkyl group comprises 1 to 6, such as 1 to 4, such as 1 to 3, such as 2 to 3 or such as 1 to 2 carbon atoms. The term includes the subclasses n-alkyl, secondary alkyl and tertiary alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl and isohexyl.
The terms "alkyloxy" and "alkoxy" are intended to denote a group of the formula-OR ', wherein R' is an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom, e.g., a methoxy group (-OCH)3) Ethoxy (-OCH)2CH3) N-propoxy, isopropoxy, butoxy, tert-butoxy and the like.
The term "hydroxyalkyl" is intended to mean an alkyl group as defined above substituted with one or more hydroxyl groups, e.g. hydroxymethyl, hydroxyethyl, hydroxypropyl.
The term "halogen" is intended to denote a substituent from group seven of the periodic table of the elements, such as fluorine, chlorine and bromine, preferably fluorine.
The term "haloalkyl" is intended to mean an alkyl group as defined herein, e.g. fluoromethyl, difluoromethyl or trifluoromethyl, substituted with one or more halogen atoms as defined herein, e.g. fluoro or chloro.
The terms "haloalkyloxy" and "haloalkoxy" are intended to mean a haloalkyl group, as defined herein, attached to the parent molecular moiety through an oxygen atom, e.g., difluoromethoxy or trifluoromethoxy.
As used herein, the term "cycloalkyl" is intended to mean a saturated cycloalkane group. The cycloalkyl group contains 3 to 7 carbon atoms, such as 3 to 6 carbon atoms, such as 3 to 5 carbon atoms or such as 3 to 4 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
The term "bridged cycloalkyl" is intended to mean a saturated carbocyclic ring having the indicated number of carbon atoms and comprising one or two carbon bridges. Representative examples include, but are not limited to, norbornyl, nortricyclyl, bicyclo [1.1.1] pentyl.
The term "heteroaryl" is intended to mean a group comprising a monocyclic heteroaromatic ring of a 5-or 6-membered ring, said 5-or 6-membered ring comprising 1 to 5 carbon atoms and 1 to 4 heteroatoms selected from O, N or S. The heteroaryl group can be attached to the parent molecular moiety through a carbon atom or a nitrogen atom contained anywhere in the heteroaryl group. Representative examples of (5-6) -membered heteroaryl groups include, but are not limited to, furyl, imidazolyl, isothiazolyl
The term "6-membered heteroaryl" is intended to mean a group of monocyclic heteroaromatic rings, which comprises 6-membered rings, i.e. having a ring size of 6 atoms, which comprises 1-5 carbon atoms and 1-5 heteroatoms, e.g. 1 heteroatom, e.g. 1-2 heteroatoms, e.g. 1-3 heteroatoms, e.g. 1-4 heteroatoms, wherein the heteroatom is N. Representative examples of 6-membered heteroaryl groups include, but are not limited to, pyrazinyl, pyridazinyl, pyridyl, pyrimidinyl, and triazinyl.
As used herein, the term "heteroaryloxy" refers to the group heteroaryl-O-, wherein "heteroaryl" is as described above. Representative examples of 6-membered heteroaryloxy include, but are not limited to, pyrazinyloxy, pyridazinyloxy, pyridinyloxy, pyrimidinyloxy, triazinyloxy.
The term "hydrocarbyl" is intended to mean a group containing only hydrogen and carbon atoms, which may contain one or more carbon-carbon double and/or triple bonds, and which may contain cyclic moieties in combination with branched or straight moieties. The hydrocarbon comprises from 1 to 6 carbon atoms, and preferably from 1 to 5, such as from 1 to 4, such as from 1 to 3, such as from 1 to 2 carbon atoms. The term includes alkyl, cycloalkyl and aryl groups as described herein.
In some cases, the number of carbon atoms in a hydrocarbyl group (e.g., alkyl, cycloalkyl, and aryl) is prefixed "(C)a-Cb) "means where a is the minimum number of carbons in the hydrocarbyl group and b is the maximum number of carbons in the hydrocarbyl group. Thus, for example, (C)1-C4) Alkyl is intended to mean an alkyl group containing 1 to 4 carbon atoms, and (C)3-C6) Cycloalkyl is intended to mean cycloalkyl containing from 3 to 6 carbon ring atoms.
The term "oxo" is intended to mean an oxygen atom (═ O) attached to the parent molecular moiety through a double bond.
The group "CN" is intended to represent cyano.
The group "OH" is intended to mean a hydroxyl group.
The group "C (O)" is intended to mean a carbonyl group (C ═ O).
Radical "S (O)2"is intended to mean a sulfonyl group (S (═ O)2)。
If substituents are described as being independently selected from a group, each substituent is selected independently of the other. Thus, each substituent may be the same or different from the other substituents.
The term "optionally substituted" means "unsubstituted or substituted," and thus the general formula described herein encompasses compounds containing the indicated optional substituents as well as compounds that do not contain optional substituents.
The term "pharmaceutically acceptable salt" is intended to denote a salt prepared by reacting a compound of formula I comprising a basic moiety with a suitable inorganic or organic acid, such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, 2-dichloroacetic acid, adipic acid, ascorbic acid, L-aspartic acid, L-glutamic acid, galactaric acid, lactic acid, maleic acid, L-malic acid, phthalic acid, citric acid, propionic acid, benzoic acid, glutaric acid, gluconic acid, D-glucuronic acid, methanesulfonic acid, salicylic acid, succinic acid, malonic acid, tartaric acid, benzenesulfonic acid, ethane-1, 2-disulfonic acid, 2-hydroxyethanesulfonic acid, toluenesulfonic acid, sulfamic acid, fumaric acid and ethylenediaminetetraacetic acid. Pharmaceutically acceptable salts of compounds of formula I containing an acidic moiety may also be prepared by reaction with a suitable base such as sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, silver hydroxide, aqueous ammonia and the like or a suitable non-toxic amine such as lower alkylamine, hydroxy-lower alkylamine, cycloalkylamine or benzylamine, or L-arginine or L-lysine. Other examples of pharmaceutically acceptable salts are listed in Berge, s.m.; j.pharm.sci.; (1977) 66(1),1-19, which is incorporated herein by reference.
The term "solvate" is intended to mean a substance formed by the interaction between a compound, for example a compound of formula I, and a solvent, for example alcohol, glycerol or water, wherein the substance is in crystalline form. When water is the solvent, the material is referred to as a hydrate.
The term "protic solvent" is intended to mean a solvent having an acidic hydrogen, such as water or an alcohol, such as methanol, ethanol or isopropanol.
The term "aprotic solvent" is intended to mean a solvent which does not have an acidic hydrogen, such as dichloromethane, acetonitrile, dimethylformamide, dimethyl sulfoxide or acetone.
The term "treatment" as used herein refers to the management and care of a patient for the purpose of combating a disease, disorder or condition. The term is intended to include delaying the progression of the disease, disorder or condition, the reduction, alleviation or alleviation of symptoms and complications, and/or the cure or elimination of the disease, disorder or condition. The term may also include the prevention of disorders, where prevention is understood as the management and care of a patient for the purpose of combating a disease, disorder or condition, and includes the administration of active compounds to prevent the onset of symptoms or complications. Nevertheless, prophylactic (prevention) and therapeutic (cure) treatment are two distinct aspects.
As used herein, the terms "disease," "condition," and "disorder" are used interchangeably to designate a state of a patient that is not the normal physiological state of a human.
The term "drug" as used herein refers to a pharmaceutical composition suitable for administering a pharmaceutically active compound to a patient.
The term "pharmaceutically acceptable" as used herein means suitable for normal pharmaceutical use, i.e. does not cause adverse events etc. in a patient.
Embodiments of the invention
In one aspect, the invention provides compounds of formula (I)
Wherein
R1Selected from phenyl, 6-membered heteroaryl, phenoxy and 6-membered heteroaryloxy; all of these groups are optionally substituted with one or more groups independently selected from R3Substituted with the substituent(s);
R2is selected from (C)3-C7) Cycloalkyl, bridge (C)3-C7) Cycloalkyl and (4-7 membered) heterocycloalkyl; all of these groups are optionally substituted with one or more groups independently selected from R4Substituted with the substituent(s);
R3selected from halogen, -CN, (C)1-C4) Alkyl, halo (C)1-C4) Alkyl, hydroxy (C)1-C4) Alkyl and (A)C3-C6) A cycloalkyl group;
R4selected from fluorine, -CN, -OH, (C)1-C4) Alkyl, halo (C)1-C4) Alkyl, hydroxy (C)1-C4) Alkyl, -ORx、-S(O)2Rx、-S(O)2NRaRb、-C(O)Rx、-C(O)(ORx) and-C (O) NRaRb；
RxIs selected from (C)1-C4) Alkyl and (C)3-C6) A cycloalkyl group;
Raand RbIndependently selected from hydrogen, (C)1-C4) Alkyl and (C)3-C6) A cycloalkyl group; and is
S represents a chiral sulphur atom having (R) stereochemistry; and
pharmaceutically acceptable salts, enantiomers, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates, and solvates thereof.
In another embodiment of the invention, R1Is optionally substituted by R3A substituted phenyl or phenoxy group.
In another embodiment of the invention, R3Is fluorine.
In another embodiment of the invention, R2Is piperidinyl, pyrrolidinyl or tetrahydropyranyl, all of which are optionally substituted with one or more groups independently selected from R4Is substituted with the substituent(s).
In another embodiment of the invention, R2Is piperidinyl or pyrrolidinyl, each of which is independently substituted with a-C (O) RxOR-C (O) (OR)x) Is substituted, and RxIs methyl.
In another embodiment of the invention, R2Is tetrahydropyranyl.
In another embodiment, the present invention provides a compound selected from the group consisting of:
(1R) -5- (3- (4-fluorophenyl) azetidin-1-yl) -7- ((tetrahydro-2H-pyran-4-yl) amino) -2, 3-dihydrothieno [3,2-b ] pyridine 1-oxide;
(3R) -3- [ [ (1R) -5- [3- (4-fluorophenyl) azetidin-1-yl ] -1-oxo-2, 3-dihydrothieno [3,2-b ] pyridin-7-yl ] amino ] piperidine-1-carboxylic acid methyl ester;
(3R) -3- [ [ (1R) -5- (3- (4-phenylazetidin-1-yl) -1-oxo-2, 3-dihydrothieno [3,2-b ] pyridin-7-yl ] amino ] piperidine-1-carboxylic acid methyl ester;
(1R) -5- (3- (4-fluorophenoxy) azetidin-1-yl) -7- ((tetrahydro-2H-pyran-4-yl) amino) -2, 3-dihydrothieno [3,2-b ] pyridine-1-oxide;
(3S) -3- [ [ (1R) -5- [3- (4-fluorophenoxy) azetidin-1-yl ] -1-oxo-2, 3-dihydrothieno [3,2-b ] pyridin-7-yl ] amino ] pyrrolidine-1-carboxylic acid methyl ester;
1- [ (3S) -3- [ [ (1R) -5- [3- (4-fluorophenoxy) azetidin-1-yl ] -1-oxo-2, 3-dihydrothieno [3,2-b ] pyridin-7-yl ] amino ] pyrrolidin-1-yl ] ketene;
(1R) -5- (3-phenylazetidin-1-yl) -7- ((tetrahydro-2H-pyran-4-yl) amino) -2, 3-dihydrothieno [3,2-b ] pyridine-1-oxide;
or pharmaceutically acceptable salts, enantiomers, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates, and solvates thereof.
The compounds of the invention may be obtained in crystalline form, either directly by concentration from an organic solvent or by crystallization or recrystallization from an organic solvent or a mixture of said solvent and a co-solvent, which may be organic or inorganic, such as water. The crystals may be isolated in a form substantially free of solvent or in the form of a solvate, such as a hydrate. The present invention encompasses all crystalline forms, such as polymorphs and pseudopolymorphs, and mixtures thereof.
The compounds of the present invention may or may not contain asymmetrically substituted (chiral) carbon atoms, which results in the presence of isomeric forms, such as enantiomers and possibly diastereomers. The present invention relates to all these isomers in optically pure form or in the form of mixtures thereof (e.g. racemic mixtures or partially purified optical mixtures). The compounds of the invention and intermediates in pure stereoisomeric form may be obtained by methods known in the art. The different isomeric forms may be separated by physical separation methods, such as selective crystallization and chromatographic techniques, e.g. high pressure liquid chromatography using a chiral stationary phase. Enantiomers can be separated from one another by selective crystallization of their diastereomeric salts with optically active amines or with optically active acids. The optically purified compound can then be released from the purified diastereomeric salt. Enantiomers can also be resolved by forming diastereomeric derivatives. Alternatively, enantiomers may be separated by chromatographic techniques using chiral stationary phases. Said pure stereoisomeric forms may also be derived from the corresponding pure stereoisomeric forms of suitable starting materials, provided that the reaction occurs stereoselectively or stereospecifically. If a particular stereoisomer is desired, the compound will be synthesized by stereoselective or stereospecific methods of preparation. These processes advantageously use chirally pure starting materials.
Furthermore, geometric isomers may be formed when double bonds or fully or partially saturated ring systems are present in the molecule. Any geometric isomer, such as an isolated, pure or partially purified geometric isomer or mixtures thereof, is intended to be included within the scope of the present invention.
The present invention is intended to include all isotopes of atoms occurring in the compounds of the present invention. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example, and not limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include13C and14C. isotopically-labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein using an appropriate isotopically-labeled reagent in place of a non-labeled reagent.
Medical use
Since the compound of the present invention can exhibit PDE4 inhibitory activity, the compound can be used as a therapeutic agent for the treatment of inflammatory allergic diseases such as bronchial asthma, COPD, allergic rhinitis and nephritis; autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, ulcerative colitis Crohn's disease, vitiligo, lupus, systemic lupus erythematosus and discoid lupus erythematosus; acute or chronic skin wound diseases; central nervous system diseases such as depression, amnesia, and dementia; organ diseases associated with ischemic reflux caused by heart failure, shock, cerebrovascular diseases, and the like; insulin-resistant diabetes; wounds, and the like.
In one embodiment, the compounds of the present invention are believed to be useful in the treatment, prevention, or alleviation of a skin disease or condition.
In another embodiment, the compounds of the present invention are believed to be useful in the treatment, prevention or alleviation of a skin disease or condition selected from the group consisting of: proliferative and inflammatory skin diseases, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis including irritant and allergic contact dermatitis, hand dermatitis, psoriasis vulgaris, reverse psoriasis, psoriatic arthritis, spondyloarthritis, epidermal inflammation, alopecia areata, rosacea, skin atrophy, steroid-induced skin atrophy, skin photoaging, SAPHO syndrome (synovitis, acne, impetigo, pachulosis and osteitis), acne vulgaris, hidradenitis suppurativa, urticaria, pruritus and eczema.
In another embodiment, the compounds of the present invention are believed to be useful in treating or ameliorating atopic dermatitis.
In another embodiment, the compounds of the present invention are believed to be useful in treating or ameliorating psoriasis, psoriasis vulgaris, inverse psoriasis or psoriatic arthritis.
In another embodiment, it is contemplated that the compounds of the present invention may be used to treat or ameliorate psoriasis.
In another embodiment, it is contemplated that the compounds of the present invention may be used to treat or alleviate alopecia areata.
In another embodiment, it is believed that the compounds of the present invention may be useful in treating or alleviating acne.
In another embodiment, the compounds of the present invention are believed to be useful in treating or reducing pruritis.
In another embodiment, it is contemplated that the compounds of the present invention may be used to treat or ameliorate eczema.
The compounds of the invention, optionally in combination with other active compounds, are useful for the treatment of skin diseases or disorders, in particular for the treatment of proliferative and inflammatory skin diseases, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, including irritant and allergic contact dermatitis, hand dermatitis, psoriasis vulgaris, psoriatic arthritis, spondyloarthritis, epidermal inflammation, alopecia areata, rosacea, skin atrophy, steroid-induced skin atrophy, skin photoaging, SAPHO syndrome (synovitis, acne, impetigo, pachulosis and osteitis), acne vulgaris, hidradenitis suppurativa, urticaria, pruritus and eczema.
In addition to use in human therapy, the compounds of the invention may also be used in veterinary therapy of animals, including mammals, such as horses, cattle, sheep, pigs, dogs and cats.
Pharmaceutical compositions of the invention
For therapeutic applications, the compounds of the present invention are typically in the form of pharmaceutical compositions. The present invention therefore relates to a pharmaceutical composition comprising a compound of formula (I), and optionally one or more other therapeutically active compounds, together with a pharmaceutically acceptable excipient or vehicle. The excipient must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
Conveniently, the active ingredient is present in an amount of from 0.0001 to 50% by weight of the formulation.
The compounds may be administered in dosage unit form, once or more times per day at appropriate intervals, but will generally depend on the condition of the patient and according to the prescription given by the physician. Conveniently, the dosage unit of the formulation comprises from 0.001mg to 1000mg, preferably from 0.01mg to 250mg, for example from 0.1 to 100mg, of a compound of formula (I).
Suitable dosages of the compounds of the present invention will depend, inter alia, on the age and condition of the patient, the severity of the condition being treated and other factors well known to the attending physician. The compounds may be administered orally, parenterally or topically according to various dosing schedules, for example daily or at weekly intervals. In general, the single dose will be in the range of 0.001 to 10mg/kg body weight, for example 0.01 to 5mg/kg body weight. The compounds may be administered as a bolus (i.e., one administration of the entire daily dose), or in divided doses administered twice or more daily.
In the case of topical treatment, it is more convenient to refer to a "use unit", which means a single dose that can be administered to a patient, which can be readily processed and packaged and maintained as a physically and chemically stable unit dose containing the active substance by itself or in admixture with a solid or liquid pharmaceutically acceptable diluent or carrier. The "use unit" can be administered topically to a patient in the form of a final formulation of 0.1mg to 50mg, preferably 0.2mg to 5mg, per square centimeter of skin.
It is also contemplated that in certain treatment regimens, it may be beneficial to administer the drug at longer intervals, such as every other day, weekly, or even longer intervals.
If The treatment involves The administration of another therapeutically active compound, it is recommended for The dose of said compound that is available to be consulted with Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9 th edition, J.G.Hardman and L.E.Limbird (eds.), McGraw-Hill 1995.
The administration of a compound of the invention and one or more other active compounds may be simultaneous or sequential.
Formulations include, for example, those in a form suitable for oral (including sustained or timed release), rectal, parenteral (including subcutaneous, intraperitoneal, intramuscular, intraarticular and intravenous), transdermal, ophthalmic, topical, dermal, nasal or buccal administration.
The formulations may conveniently be presented in dosage unit form and may be prepared by any method known in The art of Pharmacy, for example, but not limited to, The methods disclosed in Remington, The Science and Practice of Pharmacy, 21 st edition, 2005. All methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers, semi-solid carriers or finely divided solid carriers or a combination thereof, and then shaping the product into the desired formulation, as necessary.
For oral administration, including sustained or timed release, the compound of formula (I) may generally be present in an amount of from 0.001% to 20%, for example from 0.01% to about 10%, by weight of the composition.
Formulations of the invention suitable for oral and buccal administration may be in the form of discrete units, such as capsules, sachets, tablets, chewing gum or lozenges, each containing a predetermined amount of the active ingredient; can be in the form of powder, granules or pellets; may be in the form of a solution or suspension in an aqueous liquid or a non-aqueous liquid such as ethanol or glycerol; or in the form of a gel, nano-or micro-emulsion, oil-in-water emulsion, water-in-oil emulsion, or other dispensing system. The oil may be an edible oil such as, but not limited to, cottonseed oil, sesame oil, coconut oil, or peanut oil. Suitable dispersing or suspending agents for aqueous suspensions include synthetic or natural surfactants and viscosity-increasing agents, such as, but not limited to, tragacanth, alginates, acacia, dextran, sodium carboxymethylcellulose, gelatin, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, carbomer, polyvinylpyrrolidone, polysorbate, sorbitan fatty acid esters. The active ingredient may also be administered in the form of a bolus, electuary or paste.
Tablets may be prepared by compressing, molding or freeze-drying the active ingredient, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form, such as a powder or granules, which may optionally be mixed with: binders and/or fillers such as lactose, glucose, mannose, starch, gelatin, acacia, tragacanth, sodium alginate, calcium phosphate, microcrystalline cellulose, carboxymethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, ethyl cellulose, hydroxyethyl cellulose, polyethylene glycol, waxes, and the like; lubricants, such as sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like; disintegrants, such as starch, methylcellulose, agar, bentonite, croscarmellose sodium, sodium starch glycolate, crospovidone, and the like; or a dispersant such as polysorbate 80. Molded tablets may be prepared by molding in a suitable machine a mixture of the powdered active ingredient and a suitable carrier which has been moistened with an inert liquid diluent. The freeze-dried tablets may be formed from the drug solution in a freeze-dryer. Suitable fillers may be included.
Formulations for rectal administration may be in the form of suppositories in which the compounds of the invention are mixed with low melting water soluble or insoluble solids such as cocoa butter, hydrogenated vegetable oils, polyethylene glycols or fatty acid esters of polyethylene glycols, while elixirs may be prepared using myristyl palmitate.
Formulations suitable for parenteral administration conveniently comprise sterile oily or aqueous preparations of the active ingredient which are preferably isotonic with the blood of the recipient, for example isotonic saline, isotonic glucose solution or buffer solutions. In addition, the formulation may contain co-solvents, solubilizers and/or complexing agents. The preparation may conveniently be sterilized by, for example, filtration through a bacteria-retaining filter, addition of a sterilizing agent to the preparation, irradiation of the preparation or heating of the preparation. Liposome formulations as disclosed, for example, in Encyclopedia of pharmaceutical technology, Vol.9, 1994 are also suitable for parenteral administration.
Alternatively, the compounds of formula (I) may be presented as sterile solid formulations, for example as freeze-dried powders, which are readily dissolved in a sterile solvent immediately prior to use.
Transdermal formulations may be in the form of plasters, patches, microneedles, liposomes or nanoparticle delivery systems, or other skin formulations applied to the skin.
Formulations suitable for ocular administration may be in the form of sterile aqueous preparations of the active ingredient, which may be in microcrystalline form, for example in the form of an aqueous microcrystalline suspension. Liposomal formulations or biodegradable polymer systems, such as those disclosed in Encyclopedia of Pharmaceutical Technology, Vol.2, 1989, may also be used to provide active ingredients for ocular administration.
Formulations suitable for topical (e.g. dermal, intradermal or ophthalmic administration) include liquid or semisolid formulations, such as liniments, lotions, gels, spreads, sprays, foams, film-forming systems, microneedles, microemulsions or nanoemulsions, oil-in-water or water-in-oil emulsions, such as creams, ointments or pastes; or a solution or suspension (e.g. drops). The composition for ophthalmic treatment may additionally comprise a cyclodextrin.
For topical administration, the compounds of formula (I) may generally be present in an amount of from 0.001% to 20%, for example from 0.01% to about 10%, by weight of the composition, but may also be present in an amount up to about 100% of the composition.
Formulations suitable for intranasal or buccal administration include powders, self-propelling and spray formulations, for example aerosols and sprays. These agents are disclosed in detail, for example, in Modern pharmaceuticals, second edition, g.s.banker and c.t.rhodes (main eds.), pages 427-432, Marcel Dekker, new york; modern pharmaceuticals, third edition, g.s.banker and c.t.rhodes (main edition), pages 619 and 718-; and Encyclopedia of pharmaceutical Technology, volume 10, J.Swarbrick and J.C.Boylan (eds.), pp.191-221, Marcel Dekker, N.Y..
In addition to the above ingredients, the formulations of the compounds of formula (I) may contain one or more other ingredients such as diluents, buffers, flavouring agents, colouring agents, surfactants, thickening agents, penetration enhancers, solubility enhancers, preservatives such as methyl hydroxybenzoate (including antioxidants), emulsifying agents and the like.
When the active ingredient is administered in the form of a salt with a pharmaceutically acceptable non-toxic acid or base, preferred salts are, for example, those which are readily or sparingly soluble in water, in order to obtain a specific and suitable absorption rate.
The pharmaceutical composition may also comprise one or more other active ingredients conventionally used in the treatment of skin diseases or conditions, for example selected from glucocorticoids, vitamin D and vitamin D analogues, antihistamines, Platelet Activating Factor (PAF) antagonists, anticholinergics, methylxanthines, β -adrenergic drugs, COX-2 inhibitors, JAK inhibitors, other PDE inhibitors, salicylates, indomethacin, flufenamate, naproxen, timegadine, gold salts, penicillamine, serum cholesterol lowering agents, retinoids, zinc salts, sulfasalazine and calcineurin inhibitors.
Preparation method
The compounds of the present invention may be prepared by a variety of methods well known to those skilled in the art of synthesis. The compounds of the invention can be prepared, for example, using the reactions and techniques outlined below, as well as methods known in the art of synthetic organic chemistry or variations thereof as would be understood by one skilled in the art. Preferred methods include, but are not limited to, the methods described below. The reaction is carried out in a solvent which is suitable for the reagents and starting materials used and for the conversion carried out. Moreover, in the synthetic methods described below, it is understood that all proposed experimental conditions (including choice of solvent, reaction atmosphere, reaction temperature, duration of experiment, and method of work-up) are chosen as standard conditions for the reaction, as can be readily determined by one skilled in the art. Not all compounds belonging to a given class may be compatible with certain reaction conditions required in certain of the described processes. Such limitations on substituents compatible with reaction conditions will be apparent to those skilled in the art, and alternative methods may be used.
If desired, the compounds of the invention or any intermediates can be purified using standard procedures known to synthetic organic chemists, for example as described in "Purification of Laboratory Chemicals", 6 th edition, 2009, w.
Starting materials are known or commercially available compounds or can be prepared by conventional synthetic methods well known to those skilled in the art.
Unless otherwise indicated, reagents and solvents were obtained from commercial suppliers. Proton nuclear magnetic resonance spectra were obtained on a 400MHz Bruker AVANCE 400 spectrometer and a 500MHz Bruker AVANCE 500 spectrometer. Tetramethylsilane was used as an internal standard for proton spectroscopy. Unless a range is given, a multiple peak at the approximate midpoint will be given, defined as doublet (d), triplet (t), quartet (q), or (m). (br) represents a broad peak, and(s) represents a single peak. Thin layer chromatography was performed using Merck 6OF254 silica gel TLC plates. Visualization of TLC plates was performed using UV light (254 nm). Mass spectra were obtained on a Shimadzu LCMS-2010EV spectrometer using electrospray ionization (ESI) and/or Atmospheric Pressure Chemical Ionization (APCI).
The following abbreviations are used throughout:
ABPR automatic back pressure regulator
BINAP 2,2 '-bis (diphenylphosphino) -1,1' -binaphthyl
dba dibenzylidene acetone
DCM dichloromethane
DMSO dimethyl sulfoxide
EtOAc ethyl acetate
EtOH ethanol
HPLC high performance liquid chromatography
KOtBu tert-Butanol potassium
LCMS liquid chromatography-mass spectrometry
Me methyl group
MeCN acetonitrile
MeOH methanol
MHz megahertz
MTBE methyl tert-butyl ether
NaOMe sodium methoxide
NMR nuclear magnetic resonance
ppm parts per million
SFC supercritical fluid chromatography
TLC thin layer chromatography
General procedure
The compounds of the present invention may be prepared according to the following non-limiting general methods and examples:
scheme 1
Synthesis of 5, 7-dichloro-2, 3-dihydrothieno [3,2-b ] pyridine (preparation example 5)
As shown in scheme 1, 5, 7-dichloro-2, 3-dihydrothieno [3,2-b ] pyridine can be prepared by the method described in preparation examples 1 to 5.
Scheme 2
Synthesis of Compounds of the general formula (I) wherein R1And R2As previously defined:
as depicted in scheme 2, compounds of general formula (Int1) can be prepared by reacting 5, 7-dichloro-2, 3-dihydrothieno [3,2-b ] pyridine (preparation 5) with an amine of general formula (Int4), which is either commercially available or can be readily synthesized by methods known to those skilled in the art.
Typical reaction conditions include reacting 5, 7-dichloro-2, 3-dihydrothieno [3,2-b ]]A solution of pyridine (preparation 5) in a suitable solvent or solvent mixture, for example 1, 4-dioxane, is reacted with an amine of the formula (Int4) in the presence of a palladium catalyst and an inorganic or organic base, for example potassium tert-butoxide, potassium carbonate or cesium carbonate. A suitable palladium catalyst is Pd in the presence of BINAP2(dba)3A suitable base is potassium tert-butoxide, as described in preparation 6.
As shown in scheme 2, sulfoxides of general formula (Int2) can be prepared by reacting a compound of general formula (Int1) with a suitable oxidizing agent in a suitable solvent, optionally in the presence of a chiral catalyst. For example, EtOH/water solutions of compounds of formula (Int1) can be prepared by using NaIO4The oxidation was carried out by treatment at 0 ℃ to room temperature as described in preparation 9.
The sulphoxides of general formula (Int2) can be prepared as single enantiomers or as mixtures of enantiomers, which are then isolated by methods known to the person skilled in the art. Alternatively, it is also possible to preference subject the compounds to subsequent reactions in the form of mixtures of enantiomers and to the subsequent separation of the enantiomers, as described in example 1.
As shown in scheme 2, the compounds of formula (I) can be prepared by reacting a compound of formula (Int2) with a compound of formula R1NH2Are commercially available or can be readily synthesized by methods known to those skilled in the art. Typical reaction conditions include the reaction of a solution of a compound of formula (Int2) in a suitable solvent or solvent mixture such as 1, 4-dioxane with a compound of formula R1NH2In the presence of a palladium catalyst and an inorganic or organic base such as potassium tert-butoxide, potassium carbonate or cesium carbonate. A suitable palladium catalyst is palladium acetate in the presence of BINAP and a suitable base is cesium carbonate, as described in example 1. The compounds of formula (I) may be initially synthesized as a mixture of enantiomers which are then isolated by methods known to those skilled in the art.
Alternatively, as shown in scheme 2, compounds of formula (Int3) can also be prepared by reacting compounds of formula (Int1) with formula R1NH2Are commercially available or can be readily synthesized by methods known to those skilled in the art. Typical reaction conditions include the reaction of a solution of a compound of formula (Int1) in a suitable solvent or solvent mixture such as 1, 4-dioxane with a compound of formula R1NH2In the presence of a palladium catalyst and an inorganic or organic base such as potassium tert-butoxide, potassium carbonate or cesium carbonate. A suitable palladium catalyst is Pd in the presence of BINAP2(dba)3A suitable base is potassium tert-butoxide, as described in preparation example 12.
As shown in scheme 2, the compounds of general formula (I) can then be prepared by reacting a compound of general formula (Int3) with a suitable oxidizing agent in a suitable solvent, optionally in the presence of a chiral catalyst. For example, EtOH/water solutions of compounds of formula (Int3) can be prepared by using NaIO4The oxidation was carried out by treatment at 0 ℃ to room temperature, as described in example 7.
Scheme 3
Another method for the synthesis of compounds of the general formula (Int2), wherein R1And R2As previously defined:
as shown in scheme 3, sulfoxides of formula (Int5) can be prepared by reacting 5, 7-dichloro-2, 3-dihydrothieno [3,2-b ]]Pyridine (preparation 5) with a suitable oxidizing agent in a suitable solvent, optionally in the presence of a chiral catalyst. For example, 5, 7-dichloro-2, 3-dihydrothieno [3,2-b ]]EtOH/water solutions of pyridine (preparation 5) were prepared by dissolving in NaIO4The oxidation is carried out by treatment at 0-room temperature.
As shown in scheme 3, compounds of general formula (Int2) can be prepared by reacting a sulfoxide (Int5) with an amine of general formula (Int4), which is either commercially available or readily synthesized by methods known to those skilled in the art. Typical reaction conditions include reacting a sulfoxide (Int5) with an appropriate amine of formula (Int3) in an appropriate protic or aprotic solvent at a temperature from room temperature to the boiling point of the solvent in the presence of an added organic or inorganic base.
Alternatively, compounds of the general formula (Int2) can also be prepared from sulfoxides (Int5) by reaction with amines of the general formula (Int4) in a suitable solvent or solvent mixture, e.g. 1, 4-dioxane, in the presence of a palladium catalyst and a suitable inorganic or organic base, e.g. potassium tert-butoxide, potassium carbonate or cesium carbonate.
Preparation examples and examples
Preparation example 1
3-amino-4, 5-dihydrothiophene-2-carboxylic acid methyl ester
Acrylonitrile (76.2mL,1.13mol) was added to a stirred solution of NaOMe (61.0g,1.13mol) and methyl 2-thioglycolate (86mL,0.943mol) in MeOH (600mL) at 0 deg.C. The reaction mixture was stirred at room temperature for 2 days. The reaction was cooled to 0 ℃ and quenched with aqueous citric acid (1000 mL). The reaction was then extracted with EtOAc and the organic layer was washed with water. The organic layer was washed with Na2SO4Drying and concentrating under reduced pressure to obtain crude productA compound (I) is provided. MTBE was added to the crude product and the solid formed was filtered to give the title compound as a solid.1H NMR(CDCl3,500MHz):(ppm)7.12-7.04(m,2H),3.57(s,3H),2.98-2.88(m,2H),2.85-2.76(m,2H)；LCMS(ESI):m/z 160[M+H]+(ii) a 99 percent; RT ═ 1.40 min; (AQUITY UPLC BEH C18 column, 0.1% aqueous formic acid with MeCN).
Preparation example 2
3- (3-methoxy-3-oxopropionylamino) -4, 5-dihydrothiophene-2-carboxylic acid methyl ester
Mixing KHCO with water3(118.6g,1.18mol) was added to a stirred solution of the compound of preparation 1 (42.0g,264.2mmol) in DCM (500mL) at 0 deg.C. After stirring for 5 minutes, a solution of methylmalonyl chloride (42.6mL,396.2mmol) in DCM (150mL) was added slowly at 0 ℃. The reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction, the solid was filtered off and the filtrate was concentrated in vacuo to give the crude product. MTBE (65mL) was added to the crude product and the resulting suspension was filtered to give the title compound as a solid. This compound was used in the next step without further purification.1H NMR(CDCl3,400MHz):(ppm)11.08-10.98(m,1H),3.81(d,J＝6.6Hz,6H),3.63(t,J＝8.6Hz,2H),3.44(s,2H),3.18(t,J＝8.7Hz,2H)；LCMS(ESI):m/z 260[M+H]+(ii) a 97 percent; RT is 1.85 min; (AQUITYLPLC BEH C18 column, 0.1% aqueous formic acid containing MeCN).
Preparation example 3
7-chloro-5-oxo-2, 3,4, 5-tetrahydrothieno [3,2-b ] pyridine-6-carboxylic acid methyl ester
The compound of preparation 2 (42.0g,174mmol) and 30% NaOMe in MeOH (193mL,1.04mol) were stirred at 70 ℃ for 1 h. After all starting material was consumed (monitored by TLC), the reaction was cooled to 0 ℃ and aqueous citric acid was added to bring the pH to about 4. General shapeThe resulting precipitate was filtered and washed with cold water to give the pure title compound as a solid.1HNMR(DMSO-d6,400MHz):(ppm)13.20-13.14(m,1H),12.08-11.98(m,1H),3.80(s,3H),3.36-3.32(m,2H),3.19-3.08(m,2H)；LCMS(ESI):m/z 228[M+H]+(ii) a 99 percent; RT ═ 1.29 min; (AQUITY UPLC BEH C18 column, 0.1% aqueous formic acid with MeCN).
Preparation example 4
2, 3-dihydrothieno [3,2-b ] pyridine-5, 7-diol
A mixture of the compound of preparation 3 (2.20g,9.69mmol) and 2M NaOH (46mL,92mmol) was heated under reflux for 3 hours. The reaction mixture was cooled to 0 ℃ and aqueous citric acid was added to bring the pH to about 7. The precipitate formed was filtered, washed with cold water and dried under reduced pressure to give the title compound.1H NMR(DMSO-d6,500MHz):(ppm)11.33-11.00(m,1H),11.52-10.81(m,1H),5.48-5.38(m,1H),3.25-3.20(m,2H),3.09-2.95(m,2H)；LCMS(ESI):m/z 170[M+H]+(ii) a 98 percent; RT ═ 1.42 min; (AQUITY UPLC BEH C18 column, 0.1% aqueous formic acid with MeCN).
Preparation example 5
5, 7-dichloro-2, 3-dihydrothieno [3,2-b ] pyridine
N, N-dimethylaniline (10.1mL,79.8mmol) was added slowly to a stirred POCl solution of the compound of preparation 4 (3.0g,17.8mmol) at 0 deg.C3(6.76mL,72.8mmol) and the resulting reaction mixture was stirred in a sealed tube at 155 ℃ for 16 h. The reaction mixture was then cooled to room temperature and poured into ice-cold water. The mixture was extracted with EtOAc (2 × 100mL), and the combined organic layers were washed with brine, dried over anhydrous Na2SO4Dried and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (100-200 mesh) (5-15% EtOAc in petroleum ether as eluent) to afford the title compound as a solidA compound (I) is provided.1H NMR(CDCl3,400MHz):(ppm)7.12(s,1H),3.67-3.17(m,4H)；LCMS(ESI):m/z206[M+H]+(ii) a 88 percent; RT 2.10 min; (AQUITY UPLC BEH C18 column, 0.1% aqueous formic acid with MeCN).
Preparation example 6
7-chloro-5- (3- (4-fluorophenyl) azetidin-1-yl) -2, 3-dihydrothieno [3,2-b ] pyridine
Mixing KO with watertBu (3.90g,35.0mmol) was added to a stirred solution of the compound from preparation 5 (2.4g,11.7mmol) and 3- (4-fluorophenyl) azetidine (2.19g,11.7mmol) in 1, 4-dioxane (23 mL). Stirring for 5min, and adding Pd2(dba)3(1.06g,1.16mmol) and BINAP (720mg,1.16 mmol). The reaction mixture was heated at 70 ℃ for 2 hours. Then cooled to room temperature and filtered through a pad of celite, washing with EtOAc. The filtrate was concentrated under reduced pressure to give the crude product, which was subjected to flash chromatography, eluting with 20% EtOAc in hexanes as the eluent to give the pure title compound as a solid.1HNMR(DMSO-d6,400MHz):(ppm)7.52-7.38(m,2H),7.25-7.14(m,2H),6.38(s,1H),4.31(t,J＝8.0Hz,2H),3.99-3.90(m,1H),3.89-3.82(m,2H),3.38-3.34(m,2H),3.29-3.22(m,2H)；LCMS(ESI):m/Z 320[M+H]+(ii) a 99 percent; RT 2.01 min; (AQUITY UPLC BEH C18 column, 0.1% aqueous formic acid with MeCN).
Preparation example 7
7-chloro-5- (3-phenylazetidin-1-yl) -2, 3-dihydrothieno [3,2-b ] pyridine
The title compound was prepared using the same method as preparation 6, using the compound of preparation 5 and 3-phenylazetidine as starting materials. The product was obtained in solid form.1H NMR(DMSO-d6,400MHz):(ppm)7.38-7.28(m,4H),7.28-7.18(m,1H),6.38(s,1H),4.32(t,J＝7.9Hz,2H),3.97-3.90(m,1H),3.90-3.86(m,2H),3.38-3.33(m,2H),3.29-3.22(m,2H)；LCMS(ESI):m/z 303[M+H]+(ii) a 92 percent; RT 2.73 min; (AQUITY UPLC BEH C18 column, 0.1% aqueous formic acid with MeCN).
Preparation example 8
7-chloro-5- (3- (4-fluorophenoxy) azetidin-1-yl) -2, 3-dihydrothieno [3,2-b ] pyridine
Oxy) the nitrogen-labeled heterocyclic butanes were used as preparative examples using the starting materials and materials. 6 the product was obtained in the same form. 51N-formation of M and R of H (and CD3-C (l 4)3Fluorine 40 benzene 0MHz) (ppm)7.05-6.94(m,2H),6.79-6.60(m,2H),6.14(s,1H), 5.12-4.97 (m,1H),4.42-4.25(m,2H),4.09-3.91(m,2H),3.36-3.32(m,2H),3.26-3.23(m, 2H); LCMS (ESI) M/z 337[ M + H]+(ii) a 93 percent; RT 2.43 min; (AQUITY UPLC BEH C18 column, 0.1% aqueous formic acid with MeCN).
Preparation example 9
7-chloro-5- (3- (4-fluorophenyl) azetidin-1-yl) -2, 3-dihydrothieno [3,2-b ] pyridine-1-oxide
NaIO is introduced4(2.1g,9.96mmol) was added to a stirred solution of the compound of preparation 6 (2.9g,9.06mmol) in EtOH/H2O (6.0mL,1:1 ratio) and the reaction was stirred at room temperature for 16 h. After completion of the reaction (monitored by TLC), the reaction was diluted with EtOAc and the organic layer was separated and Na was used2SO4Drying and concentration under reduced pressure gave the title compound as a solid, which was used without further purification. LCMS (ESI) M/z 337[ M + H]+(ii) a 76%; RT 2.01 min; (AQUITY UPLC BEH C18 column, 0.1% FA in water with MeCN).
Preparation example 10
7-chloro-5- (3-phenylazetidin-1-yl) -2, 3-dihydrothieno [3,2-b ] pyridine-1-oxide
The compound of preparation 7 was reacted according to the method of preparation 9 to give the title compound as a solid. LCMS (ESI) M/z 319[ M + 1]]+(ii) a 93 percent; RT ═ 1.90 min; (AQUITY UPLC BEH C18 column, 0.1% FA in water with MeCN).
Preparation example 11
7-chloro-5- (3- (4-fluorobenzyl) azetidin-1-yl) -2, 3-dihydrothieno [3,2-b ] pyridine-1-oxide
The compound of preparation 8 was reacted according to the method of preparation 9 to give the title compound as a solid.1H NMR(CDCl3,400MHz):(ppm)7.09-6.86(m,2H),6.79-6.58(m,2H),6.20(s,1H),5.15-5.01(m,1H),4.55-4.36(m,2H),4.22-4.11(m,2H),3.96-3.76(m,1H),3.36-3.07(m,3H)LCMS(ESI):m/z353[M+H]+(ii) a 98 percent; RT ═ 1.75 min; (AQUITY UPLC BEH C18 column, 0.1% aqueous formic acid with MeCN).
Preparation example 12
5- (3-Phenylazetidin-1-yl) -N- (tetrahydro-2H-pyran-4-yl) -2, 3-dihydrothieno [3,2-b ] pyridin-7-amine
The title compound was obtained as a solid using the compound of preparation 7 and tetrahydropyran-4-amine according to the method of example 1. LCMS (ESI) M/z 368[ M + H]+(ii) a 83 percent; RT ═ 1.93 min; (AQUITY UPLC BEH C18 column, 0.1% FA in water with MeCN).
Example 1
(1R) -5- (3- (4-fluorophenyl) azetidin-1-yl) -7- ((tetrahydro-2H-pyran-4-yl) amino) -2, 3-dihydrothieno [3,2-b ] pyridine 1-oxide
Mixing Cs2CO3(8.1g,25.0mmol) and BINAP (518mg,0.83mmol) were added to a stirred solution of the compound of preparation 9 (2.8g,8.33mmol) and tetrahydropyran-4-amine (1.2g,12.5mmol) in 1, 4-dioxane (30mL), followed by palladium acetate (186mg,0.83 mmol). The reaction mixture was heated at 100 ℃ for 16 hours. The reaction mixture was cooled to room temperature and filtered through a pad of celite, washing with EtOAc. The filtrate was concentrated under reduced pressure to give the crude product. Purification by flash chromatography eluting with 3% MeOH/DCM as eluent gave the racemic product (1.6g, 50%). Then further purified by chiral SFC using (R, R) WHELK-01 column and methanol as co-solvent. The solvent was removed in vacuo to give the title compound as a solid.1H NMR(DMSO-d6,500MHz):(ppm)7.44-7.36(m,2H),7.18(t,J＝8.9Hz,2H),6.40(d,J＝8.2Hz,1H),5.44(s,1H),4.40-4.32(m,2H),3.98-3.81(m,5H),3.73-3.63(m,1H),3.52-3.35(m,3H),3.27-3.21(m,1H),3.05-2.95(m,1H),2.93-2.86(m,1H),1.92-1.85(m,2H),1.64-1.51(m,2H)；LCMS(ESI):m/z 402[M+H]+(ii) a 99 percent; RT ═ 1.64 min; (AQUITY UPLC BEH C18 column, 0.1% aqueous formic acid solution containing MeCN) and chiral HPLC-99% SFC method: injection volume: 14. mu.l, cosolvent: methanol, column (R, R) WHELK-01 (4.6X 250) mm,5u, temperature: 30 ℃, flow rate: 4, pressure: 100, RT:5.39 min.